Short Interest in IQVIA Holdings Inc. (NYSE:IQV) Drops By 20.6%

IQVIA Holdings Inc. (NYSE:IQV) saw a large decline in short interest in the month of December. As of December 31st, there was short interest totaling 3,735,524 shares, a decline of 20.6% from the December 15th total of 4,704,477 shares. Based on an average trading volume of 1,165,163 shares, the days-to-cover ratio is presently 3.2 days. Approximately 2.2% of the company’s shares are sold short. Approximately 2.2% of the company’s shares are sold short. Based on an average trading volume of 1,165,163 shares, the days-to-cover ratio is presently 3.2 days.

IQVIA Stock Down 1.7%

Shares of NYSE IQV traded down $3.92 during midday trading on Tuesday, reaching $233.76. 818,382 shares of the company’s stock traded hands, compared to its average volume of 1,226,838. The company has a market cap of $39.81 billion, a price-to-earnings ratio of 32.07, a P/E/G ratio of 2.42 and a beta of 1.36. The stock’s 50 day simple moving average is $227.80 and its 200-day simple moving average is $204.13. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. IQVIA has a one year low of $134.65 and a one year high of $247.04.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. The company had revenue of $4.10 billion during the quarter, compared to the consensus estimate of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. IQVIA’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, analysts predict that IQVIA will post 10.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

IQV has been the topic of a number of research analyst reports. Cowen cut shares of IQVIA from a “buy” rating to a “hold” rating in a report on Monday, November 3rd. Robert W. Baird set a $258.00 price objective on shares of IQVIA and gave the company an “outperform” rating in a research report on Wednesday, October 29th. Wall Street Zen lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Saturday. Hsbc Global Res raised shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 9th. Finally, Barclays set a $230.00 price objective on IQVIA in a research note on Monday, December 15th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $249.19.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the sale, the insider owned 27,108 shares in the company, valued at $5,955,627.60. This trade represents a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.60% of the stock is owned by company insiders.

Institutional Trading of IQVIA

Hedge funds have recently modified their holdings of the company. Claret Asset Management Corp raised its stake in shares of IQVIA by 1.1% during the 3rd quarter. Claret Asset Management Corp now owns 4,527 shares of the medical research company’s stock worth $860,000 after acquiring an additional 49 shares in the last quarter. Versant Capital Management Inc grew its holdings in IQVIA by 6.3% in the third quarter. Versant Capital Management Inc now owns 899 shares of the medical research company’s stock worth $171,000 after purchasing an additional 53 shares during the last quarter. Leonard Rickey Investment Advisors P.L.L.C. increased its position in shares of IQVIA by 3.3% during the fourth quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 1,814 shares of the medical research company’s stock worth $409,000 after purchasing an additional 58 shares in the last quarter. Brookstone Capital Management boosted its position in shares of IQVIA by 2.2% in the 4th quarter. Brookstone Capital Management now owns 2,931 shares of the medical research company’s stock worth $661,000 after purchasing an additional 63 shares in the last quarter. Finally, Private Advisor Group LLC grew its stake in IQVIA by 1.0% during the 3rd quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock worth $1,163,000 after buying an additional 63 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.